Recently funded by the National Institutes of Health (NIH), LJI is working to confirm useful epitope region by examining neutralizing antibodies of convalescent COVID-19 patients.

Smith College

- La Jolla Institute for Immunology (LJI) 
- University of Cambridge/DIOSynVax
- Immunonomic Therapeutics/EpiVax/PharmaJet

current studies identifying epitopes

Shin, M.D., Shukla, S., Chung, Y.H. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020). doi: 10.1038/s41565-020-0737-y

https://doi.org/10.1038/s41565-020-0737-y

COVID-19 vaccine development and a potential
nanomaterial path forward

current studies identifying epitopes by La Jolla
Institute for Immunology (LJI) 

"using immunoinformatics-derived peptide sequences of S protein in their vaccine formulations (https://oncogen.ro/oncogen-vaccine-design-for-coronavirus/;
https://www.cam.ac.uk/research/news/cambridge-research-teamworking-towards-vaccine-against-covid-19)"

current studies identifying epitopes by University of Cambridge/DIOSynVax

"Immunonomic Therapeutics/EpiVax/PharmaJet are leveraging in silico T-cell epitope prediction72. The use of B-cells epitopes appears practical because of its universality compared to the HLA-restricted T-cell specific vaccines."

Learn Before

Related